Brain Tumor News and Research

RSS

A Brain Tumor is the growth of abnormal cells in the tissues of the brain. Brain tumors can be benign (not cancer) or malignant (cancer).

Brain cancer survivor completes journey across America to raise awareness, money for brain cancer research

Anne Feeley, a 56-year-old mother and brain cancer survivor, completed her journey across America today, cycling 3,708 miles, to raise awareness and money for brain cancer research and patient care. Feeley pedaled the last 6.5 miles of her journey from Hains Point, VA to cross the finish line at the Capital Reflecting Pool in Washington, DC.

19 Jul 2010

Meningiomas account for about 25% of primary brain tumors: Mayo Clinic Health Letter

Meningiomas, the most common type of brain tumors, are rarely cancerous and may not require treatment. The July issue of Mayo Clinic Health Letter offers an overview of this brain tumor that is usually benign.

16 Jul 2010

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

The medical standard of care - comprised of surgery, radiation and chemotherapy - for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

15 Jul 2010

President Obama shoots a basket in 'Quest' to raise awareness about brain tumors

Thirteen year-old basketball enthusiast and brain tumor patient Justin Friedlander had the biggest thrill of his young life on Tuesday when he shot baskets with President Obama in hopes of helping to find a cure for brain tumors.

12 Jul 2010

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

Ambulance services to improve in Victoria promises Health Minister

With increasing concern over ambulance services Health Minister Daniel Andrews has admitted that there are gaps in Victoria’s ambulance services and once new paramedics arrive the problem will be addressed under the government's regional ambulance policy.

29 Jun 2010

St. Jude Children's Research Hospital ranked among top 10 "Best Places to Work in Academia"

St. Jude Children's Research Hospital is ranked as one of the top institutions in the annual "Best Places to Work in Academia" list by The Scientist magazine. This is the fifth consecutive year St. Jude made the publication's top 10 list of institutions in the United States. The hospital ranks second in the country behind Princeton University.

29 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

Conscious sedation for glioma resection shortens hospital stay

The recovery time and cost of brain-tumor surgery might both be reduced if surgery is performed while patients are awake during part of the procedure, according to a new study conducted at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

19 Jun 2010

Damage to right prefrontal cortex of brain leads to deficit in intentional anticipation

Researchers of the University of Granada have demonstrated that patients who have damage to the right prefrontal cortex of the brain -the part involved in anticipation and quick reaction to stimuli- present a deficit in intentional anticipation (for example, when we put the vehicle in gear before the light turns green). However, these patients keep unintentional anticipation functions intact, which could help develop new therapies.

18 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

16 Jun 2010

Uncork the Cure to contribute funds for children's brain tumor research

Uncork the Cure – a festival involving wine, food and music – will contribute funds for research into the causes of and cure for children's gliomas or brain tumors.

11 Jun 2010

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

10 Jun 2010

Voices Against Brain Cancer's fifth annual gala to fight brain cancer

Voices Against Brain Cancer's fifth annual gala, Sounding Off For A Cure, to fight brain cancer. Proceeds from the event will benefit innovative brain cancer research programs at, Columbia, Cornell, Duke, Harvard, Memorial Sloan-Kettering, University of Michigan, University of Pittsburg and Brookhaven National Laboratory.

10 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas

Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.

8 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.